177Lu-Dotatate plus octreotide was not superior in overall survival compared to octreotide alone for neuroendocrine tumours
1. The median overall survival for patients receiving177Lu-Dotatate and intramuscular, long-acting octreotide was 47.0 months and 36.3 months respectively 2. ...